BBVA has formed a strategic partnership with investment firm KKR, committing $200 million to support KKR’s Global Climate Strategy, which focuses on large-scale climate infrastructure projects like ...

Scila AB, a leader in trade surveillance and risk management technology, has announced that Erste Group, a major European financial institution, has successfully implemented Scila Surveillance. The ...

Scila AB, a leader in trade surveillance and risk management technology, has announced that Erste Group, a major European financial institution, ...

Open a VIP account (an enterprise account with priority handling, 24/7 dedicated customer care, unlimited usage/users, help on formatting, standards, rules, regulations, policy compliance, etc., and ...

Fresenius Kabi, in collaboration with Formycon, has received approval from the European Commission (EC) for FYB202, a biosimilar of ustekinumab (marketed as Stelara® by Johnson & Johnson). This ...

Fresenius Kabi, in collaboration with Formycon, has received approval from the European Commission (EC) for FYB202, a biosimilar of ustekinumab (marketed as Stelara® by Johnson & Johnson). This ...

BBVA has formed a strategic partnership with investment firm KKR, committing $200 million to support KKR’s Global Climate ...

(IN BRIEF) Wolters Kluwer has launched CCH iFirm Validate, a new cloud-based module designed to enhance audit processes by using blockchain technology for secure and efficient bank confirmations and ...

Fresenius Kabi, in collaboration with Formycon, has received approval from the European Commission (EC) for FYB202, a biosimilar of ustekinumab ( ...

(IN BRIEF) Fresenius Kabi, in collaboration with Formycon, has received approval from the European Commission (EC) for FYB202, a biosimilar of ustekinumab (marketed as Stelara® by Johnson & Johnson).

Wolters Kluwer has launched CCH iFirm Validate, a new cloud-based module designed to enhance audit processes by using ...

(IN BRIEF) Fresenius Kabi, in partnership with Formycon AG, has received European Commission approval for Otulfi®, a biosimilar of ustekinumab. This new product, authorized for both subcutaneous and ...